联合王国批准新药丸Ryeqo用于内分泌硬化治疗,首次提供每日家庭使用选择。 New pill Ryeqo approved for endometriosis treatment in the UK, offering a first daily home-use option.

国家卫生和护理英才研究所批准了一种新的避孕药Relugolix-estradiool- nonethisterone(Ryeqo),用于在国民保健体系上治疗内分泌硬化。 The National Institute for Health and Care Excellence (Nice) has approved a new pill, relugolix–estradiol–norethisterone (Ryeqo), for treating endometriosis on the NHS. 这是该病症的第一个长期每日避孕药片,影响到约150万联合王国妇女。 This is the first long-term daily pill for the condition, affecting about 1.5 million UK women. 药丸可以在家里服用,工作速度更快,并将必要的荷尔蒙结合到一种药丸中,减少门诊就诊次数。 The pill can be taken at home, works faster, and combines necessary hormones in one pill, reducing clinic visits. 没有接受其他治疗的病人可以使用它。 It's available to patients who have not responded to other treatments.